XML 49 R41.htm IDEA: XBRL DOCUMENT v3.25.3
Grant Revenue - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 01, 2024
Sep. 19, 2022
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Oct. 04, 2024
Disaggregation of Revenue [Line Items]                
Revenue recognized     $ 1,397,000 $ 1,456,000 $ 3,846,000 $ 4,412,000    
CPRIT Contract [Member]                
Disaggregation of Revenue [Line Items]                
Grant funding term   3 years            
CPRIT grant funding term, description         The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of REYOBIQ based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements.      
Contract effective date   Aug. 31, 2022            
Percentage of aggregate amount of proceeds awarded under CPRIT grant   400.00%            
Percentage of grant proceeds with interest not exceed annually   5.00%            
CPRIT Contract [Member] | Grant [Member]                
Disaggregation of Revenue [Line Items]                
Deferred grant liability     1,100,000   $ 1,100,000    
Revenue recognized     1,400,000 $ 3,800,000 1,500,000 $ 4,400,000    
Grant revenue receivable         600,000  
Congressionally Directed Medical Research Programs [Member]                
Disaggregation of Revenue [Line Items]                
Amount to be received as award for research and development $ 3,000,000              
Department of Defense Award [Member]                
Disaggregation of Revenue [Line Items]                
Grant revenue         $ 0   $ 0  
Research and development award in period 3 years              
First payment received               $ 900,000